Información de Alkermes Plc, dividendo de Alkermes Plc, actividades de los accionistas y más

Más Datos de Alkermes Plc Compañía

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Información de Alkermes Plc



Símbolo de cotizaciónALKS

Nombre de la empresaAlkermes Plc

Fecha de salida a bolsaJul 16, 1991

Director ejecutivoMr. Richard F. Pops

Número de empleados1800

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 16

DirecciónConnaught House

CiudadDUBLIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísIreland

Código postalD04 C5Y6

Teléfono35317728000

Sitio Webhttps://www.alkermes.com/

Símbolo de cotizaciónALKS

Fecha de salida a bolsaJul 16, 1991

Director ejecutivoMr. Richard F. Pops

Ejecutivos de Alkermes Plc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

Otro

21.09M

5.40%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

Otro

21.09M

5.40%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

Otro

59.83%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

Otro

59.83%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

53.57%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

14.45%

Research Firm

3.16%

Pension Fund

2.38%

Individual Investor

1.65%

Sovereign Wealth Fund

1.18%

Private Equity

0.61%

Bank and Trust

0.44%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

743

174.30M

105.56%

-28.06M

2025Q2

770

179.09M

108.49%

-26.85M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

23.73M

14.37%

-251.67K

-1.05%

Jun 30, 2025

The Vanguard Group, Inc.

18.45M

11.18%

+290.40K

+1.60%

Jun 30, 2025

T. Rowe Price Associates, Inc.

9.86M

5.97%

-1.76M

-15.13%

Jun 30, 2025

State Street Investment Management (US)

8.21M

4.97%

+185.59K

+2.31%

Jun 30, 2025

Baker Bros. Advisors LP

6.41M

3.88%

+1.93M

+42.99%

Jun 30, 2025

Renaissance Technologies LLC

5.81M

3.52%

+71.33K

+1.24%

Jun 30, 2025

RTW Investments L.P.

4.68M

2.84%

-2.20M

-31.99%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.02M

2.44%

+83.86K

+2.13%

Jun 30, 2025

American Century Investment Management, Inc.

3.66M

2.22%

+191.55K

+5.53%

Jun 30, 2025

JP Morgan Asset Management

3.95M

2.39%

-179.85K

-4.36%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

AdvisorShares Psychedelics ETF

5.6%

iShares Neuroscience and Healthcare ETF

4.16%

Invesco S&P SmallCap Health Care ETF

3.15%

First Trust NYSE Arca Biotechnology Index Fund

3.08%

ALPS Medical Breakthroughs ETF

2.88%

Knowledge Leaders Developed World ETF

1.7%

Abacus FCF International Leaders ETF

1.46%

Langar Global HealthTech ETF

1.46%

SPDR S&P Biotech ETF

1.39%

Invesco S&P SmallCap Quality ETF

1.33%

AdvisorShares Psychedelics ETF

Proporción5.6%

iShares Neuroscience and Healthcare ETF

Proporción4.16%

Invesco S&P SmallCap Health Care ETF

Proporción3.15%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.08%

ALPS Medical Breakthroughs ETF

Proporción2.88%

Knowledge Leaders Developed World ETF

Proporción1.7%

Abacus FCF International Leaders ETF

Proporción1.46%

Langar Global HealthTech ETF

Proporción1.46%

SPDR S&P Biotech ETF

Proporción1.39%

Invesco S&P SmallCap Quality ETF

Proporción1.33%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos